Two leading mitochondria-targeted compounds, MitoQ and SS-31 (elamipretide), were compared in the same mouse model of fatty liver, and they were not interchangeable. Both cut liver fat, dampened NF-κB and NLRP3 inflammation, and improved insulin-signaling markers. MitoQ showed the stronger antioxidant signature, while SS-31 did better at preserving mitochondrial structure. But this was a study in aged female mice, with different doses and routes for each drug. Here is what the results show, what they don't, and why the research-peptide market deserves caution.
This page is available in